Oncotelic Therapeutics, Inc. (OTLC)
About Oncotelic Therapeutics, Inc.
ONCOTELIC THERAPEUTCS INC
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2023
- $70.0K
- Net income
- $249.3M
- Total assets
- $393.1M
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
Oncotelic Therapeutics, Inc. (OTLC) Stock Price
- Profitable — net income of $249.3M in FY2023.
- Trading 60% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Oncotelic Therapeutics, Inc..
Write a review
News about Oncotelic Therapeutics, Inc.
News & sentiment via Polygon.io
Oncotelic Therapeutics, Inc.: frequently asked questions
Is Oncotelic Therapeutics, Inc. an American company?
Oncotelic Therapeutics, Inc. is a US-based company headquartered in Aguora Hills, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Oncotelic Therapeutics, Inc. headquartered?
Oncotelic Therapeutics, Inc. is headquartered in Aguora Hills, California, United States.
Is Oncotelic Therapeutics, Inc. publicly traded?
Yes — Oncotelic Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol OTLC on the OTC.
What does Oncotelic Therapeutics, Inc. do?
Oncotelic Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
